Neuphoria Therapeutics Inc. — Form 10-K
Filed September 18, 2026 · analyzed by the Periodic Agent
10-K
— Neutral
significance 8/100
What the filing says
Wolf Company P.C. (Boston) consented to inclusion of its September 18, 2026 audit report on Neuphoria's consolidated financial statements for fiscal year ended June 30, 2026 in two Form S-3 registration statements (Nos. 333-283306, 333-284512) and one Form S-8 registration statement (No. 333-284544). This is routine auditor documentation enabling the company to use its audited financials for securities offerings and equity compensation plans.
Why this rating
Standard boilerplate auditor consent; procedurally required but economically immaterial. No financial impact or operational change.
See more from September 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.